The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo

被引：0
|
作者：
Haass, N. K. [1 ]
Smalley, K. S. [1 ]
Sproesser, K. [1 ]
Contractor, R. [1 ]
Herlyn, M. [1 ]
机构：
[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2007年 / 127卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
931
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [21] The MEK1/2 inhibitor AZD6244 (ARRY-142886) downregulates constitutive and adhesion-induced c-MAF oncogene expression and its downstream targets in human multiple myeloma.
    Tai, Yu-Tzu
    Tonon, Giovanni
    Li, Xian-Feng
    Rumizen, Matthew
    Song, Weihua
    Morrison, Aileen
    Burger, Peter
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 988A - 988A
  • [22] AZD6244 (ARRY-142886), a potent and highly selective MEK1/2 inhibitor, demonstrates anti-HIF properties, and increases the therapeutic response in a lung tumor xenograft model when combined with radiotherapy
    Shannon, Aoife M.
    Telferi, Brian A.
    Babur, Muhammed
    Smith, Paul D.
    Logie, Armelle
    Wilkinson, Robert W.
    Stratford, Ian J.
    Williams, Kaye J.
    Wedge, Steve R.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3414S - 3415S
  • [23] Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
    Yeh, Tammie C.
    Marsh, Vivienne
    Bernat, Bryan A.
    Ballard, Josh
    Colwell, Heidi
    Evans, Ron J.
    Parry, Janet
    Smith, Darin
    Brandhuber, Barbara J.
    Gross, Stefan
    Marlow, Allison
    Hurley, Brian
    Lyssikatos, Joe
    Lee, Patrice A.
    Winkler, James D.
    Koch, Kevin
    Wallace, Eli
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1576 - 1583
  • [24] Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Baldwin, Andrea
    Dombi, Eva
    Wolters, Pamela
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Fisher, Michael J.
    Kim, AeRang
    Weiss, Brian D.
    Paul, Scott M.
    Clapp, Wade
    Farrell, Kathleen
    Smith, Michaele
    Fontana, Joseph
    Brofferio, Alessandra
    Steinberg, Seth M.
    Doyle, Laurence A.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM.
    Tai, Yu-Tzu
    Li, Xian-Feng
    Breitkreutz, Iris
    Song, Weihua
    Burger, Peter
    Rumizen, Matthew
    Hideshima, Teru
    Podar, Klaus
    Ghobrial, Irene
    Schlossman, Robert
    Richardson, Paul
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 987A - 987A
  • [26] SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Gross, Andrea
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Blakeley, Jaishri
    Whitcomb, Patricia
    Holmblad, Marielle
    Maritin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm
    Glod, John
    Steinberg, Seth
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2018, 20 : 143 - 144
  • [27] SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Blakeley, Jaishri O'Neill
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm A.
    Glod, John
    Steinberg, Seth M.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
    Banerji, Udai
    Camidge, D. Ross
    Verheul, Henk M. W.
    Agarwal, Roshan
    Sarker, Debashis
    Kaye, Stan B.
    Desar, Ingrid M. E.
    Timmer-Bonte, Johanna N. H.
    Eckhardt, S. Gail
    Lewis, Karl D.
    Brown, Kathryn H.
    Cantarini, Mireille V.
    Morris, Clive
    George, Sarah M. A.
    Smith, Paul D.
    van Herpen, Carla M. L.
    CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1613 - 1623
  • [29] Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Coyne, Geraldine Helen O'Sullivan
    Gross, Andrea M.
    Dombi, Eva
    Tibery, Cecilia
    Carbonell, Amanda
    Takebe, Naoko
    Derdak, Joanne
    Pichard, Dominique
    Srivastava, Apurva K.
    Herrick, William
    Parchment, Ralph E.
    Martin, Staci
    Wolters, Pamela
    Whitcomb, Patricia
    Rubinstein, Lawrence
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines
    Garon, Edward B.
    Finn, Richard S.
    Hosmer, Wylie
    Dering, Judy
    Ginther, Charles
    Adhami, Shahriar
    Kamranpour, Naeimeh
    Pitts, Sharon
    Desai, Amrita
    Elashoff, David
    French, Tim
    Smith, Paul
    Slamon, Dennis J.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (07) : 1985 - 1994
12345